GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells $20,616.57 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 263 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $78.39, for a total value of $20,616.57. Following the completion of the sale, the chief financial officer now directly owns 23,406 shares of the company’s stock, valued at approximately $1,834,796.34. The trade was a 1.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The shares were sold at an average price of $73.76, for a total transaction of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total value of $18,248.40.
• On Monday, September 9th, Kevin Feeley sold 895 shares of GeneDx stock. The stock was sold at an average price of $33.33, for a total value of $29,830.35.

GeneDx Stock Down 2.8 %

WGS stock traded down $2.19 during trading on Tuesday, reaching $75.05. 574,766 shares of the company were exchanged, compared to its average volume of 543,719. The company has a 50-day moving average of $64.42 and a two-hundred day moving average of $42.26. GeneDx Holdings Corp. has a twelve month low of $1.45 and a twelve month high of $89.11. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.25. The company had revenue of $76.90 million during the quarter, compared to the consensus estimate of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The firm’s revenue was up 44.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.82) earnings per share. On average, equities analysts anticipate that GeneDx Holdings Corp. will post -0.24 EPS for the current year.

Analyst Ratings Changes

WGS has been the subject of a number of research reports. The Goldman Sachs Group raised their target price on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Wells Fargo & Company raised their price objective on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. Finally, Craig Hallum boosted their price objective on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $59.33.

Hedge Funds Weigh In On GeneDx

Hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC acquired a new position in shares of GeneDx during the 2nd quarter valued at $34,000. nVerses Capital LLC bought a new position in GeneDx in the second quarter worth approximately $50,000. CWM LLC bought a new stake in shares of GeneDx during the third quarter valued at approximately $89,000. Verition Fund Management LLC raised its position in shares of GeneDx by 12.9% during the third quarter. Verition Fund Management LLC now owns 25,845 shares of the company’s stock worth $1,097,000 after purchasing an additional 2,945 shares during the period. Finally, American Century Companies Inc. lifted its holdings in shares of GeneDx by 36.1% in the 2nd quarter. American Century Companies Inc. now owns 17,258 shares of the company’s stock worth $451,000 after purchasing an additional 4,573 shares in the last quarter. 61.72% of the stock is currently owned by institutional investors.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.